Diagnostic Products Aided By HBV Assay Approval; Q3 Index Composite Flat
This article was originally published in The Gray Sheet
Executive SummaryDiagnostic Products Corp.'s foray into the U.S. hepatitis B immunoassay market, continued strong Immulite sales and a favorable public policy environment helped push the firm's stock ahead 24.3% in the third quarter
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.